

Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence

Yangyang Wang, Francesco Sabbatino, Ling Yu, Elvira Favoino, Xinhui Wang, Matteo Ligorio, Soldano Ferrone, Joseph H. Schwab and Cristina R. Ferrone

Abstract Immunotherapy with tumor antigen (TA)-specific monoclonal antibody (mAb) has been shown to be effective in the treatment of several types of cancer. However, its efficacy is limited by the lack of response in some of the treated patients and by disease recurrence. In this chapter, following a short description of the characteristics of cancer initiating cells (CICs) and the markers used for their identification in various types of cancer, we will provide *in vitro* evidence to suggest that disease recurrence is caused by the lack of eradication of CICs by the TA-specific mAb-based immunotherapy. In addition, we will describe potential strategies to overcome this resistance mechanism which is a major obstacle to the successful application of TA-specific mAb-based immunotherapy.

Keywords Cancer initiating cells · Monoclonal antibody · Tumor antigen · Head and neck cancer · Breast cancer · Pancreatic cancer · Osteosarcoma · Disease recurrence · Combinatorial therapy

Yangyang Wang and Francesco Sabbatino equally contributed to this manuscript.

Y. Wang · F. Sabbatino · L. Yu · E. Favoino · X. Wang · M. Ligorio · S. Ferrone (✉)
C. R. Ferrone

Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
e-mail: sferrone@partners.org

Y. Wang
e-mail: ywang54@partners.org

F. Sabbatino
e-mail: fsabbatino@partners.org

J. H. Schwab
Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA

Abbreviations

ADCC	Antibody-dependent cell-mediated cytotoxicity
ALDH	Aldehyde dehydrogenase
BAAA	BODIPY TM -aminoacetaldehyde
CDC	Complement-dependent cytotoxicity
CICs	Cancer initiating cells
CSPG4	Chondroitin sulfate proteoglycan 4
CTL	Cytotoxic T cells
DEAB	Diethylaminobenzaldehyde
Grp94	Glucose-regulated protein of 94 kDa
HSP	Heat shock protein
mAb	Monoclonal antibody
MCSP	Melanoma-associated chondroitin sulfate proteoglycan
MDSC	Myeloid-derived suppressor cells
MFI	Mean fluorescence intensity
NG2	Neuron-glia antigen 2
PDAC	Pancreas ductal adenocarcinoma
SCID	Severe combined immunodeficiency
SHH	Sonic Hedgehog Homologue
T regs	T regulatory cells
TA	Tumor antigen
TNBC	Triple negative breast cancer

Introduction

The hybridoma methodology has greatly facilitated the identification of a large number of human tumor antigens (TAs) by providing highly specific probes. Several of the identified TAs meet the criteria in terms of high expression on tumor cells, restricted distribution in normal tissues and functional properties to be used as targets of monoclonal antibody (mAb)-based immunotherapy for the treatment of malignant diseases [1]. A large body of clinical evidence in conjunction with the results of studies in animal model systems have convincingly shown that targeting TA with mAbs may represent an effective strategy for the treatment of many types of cancer [1]. The therapeutic efficacy of TA-specific mAbs is in general enhanced by combination with chemo- and/or radio-therapy [1]. Nevertheless, immunotherapy with TA-specific mAbs is not effective in all the treated patients and in most patients its efficacy is limited in time because of disease recurrence and/or metastases [1]. These clinical findings have stimulated interest in defining the molecular mechanism(s) underlying the innate and acquired resistance of tumor cells to TA-specific mAb-based immunotherapy with the expectation that this

Table 1 Mechanism of cancer resistance to antibody treatment

Mechanism of resistance	Mediated mechanism	Alteration	Cancer	References
Amplification of downstream signaling and alternative signaling pathways	Independent growth stimulatory effects	(1) KRAS mutation (codon 12 or 13)	Breast, colon, cancer	[40–45]
		(2) BRAF mutation (V600E)		
Expression of immune inhibitory molecules	Inhibition of NK cells-mediated lysis by mAbs	(3) PIK3CA mutation	Colon, ovarian, cancer	[46, 47]
		(4) PTEN loss		
		(5) Overexpression of other HER family receptors		
		(6) Increased IGF-1R activity		
Expression of membrane-bound complement regulatory proteins	Inhibition of CDC	Increased HLA-G or HLA-E expression	Breast, lung, colon cancer and hematological malignancies	[48–51]
		Increased CD46, CD55, and CD59 expressions		
Impairment of proper antigen presentation	Evasion to destruction by MHC-restricted CTLs response mediated by mAbs	Down-regulation of MHC I expression	Breast cancer, colon cancer	[52–54]
Increased inhibitory signals by intratumoral Tregs or MDSCs	Suppression of the anti-cancer immune response mediated by mAbs	Apoptosis of immune effectors cells by increased production of perforin and granzyme, by expression of indolamine 2,3 dioxygenase and by production of soluble mediators such as TGF- β and IL-10	Breast cancer, hematological malignancies	[55–57]
Reduction of binding affinity of TA	Reduction of TA recognition	(1) Fc γ RII and Fc γ RIII polymorphism	Breast cancer, colon cancer, hematological malignancies	[58–60]
		(2) CD20 mutation (ANPS and YCYSI, at positions 170 to 173 and 182 to 185)		
Reduction or loss of TA expression	Reduction or loss of tumor cell recognition	(1) Genetic instability of tumor cells	Colon cancer and hematological malignancies	[61–65]
		(2) MAPK pathway activation		
Impaired access to TA or production of antagonist TA	Reduction of TA recognition	(3) increased histone deacetylase activity	Breast cancer	[66, 67]
		(1) Expression of extracellular domain-truncated HER2 (p95 HER2)		
		(2) Overexpression of MUC4		

information will contribute to the rational design of targeted therapeutic strategies to counteract these resistances.

Multiple mechanisms have been shown to underlie the resistance of tumor cells to TA-specific mAb-based immunotherapy. As recently reviewed by other groups (see Table 1) and discussed in many chapters of this book, they include loss of the targeted TA, mutations in the targeted TA, upregulation of complement component inhibitors, etc. In addition, recent evidence demonstrated that the therapeutic activity of TA-specific mAbs may be mediated by induction or enhancement of TA-specific cytotoxic T cells (CTL). If this is the case, defects in antigen presentation by tumor cells to cognate CTL or suppression of their functional properties may represent mechanisms of resistance of tumor cells to mAb-based immunotherapy.

In the present paper, utilizing our recent *in vitro* data, we will discuss the possibility that disease recurrence in patients treated with TA-specific mAb-based immunotherapy in combination with radio- and/or chemo-therapy may be caused by the resistance of cancer initiating cells (CICs) to this type of therapy. Specifically, we will describe (1) the characteristics of CICs in the tumors we have investigated; (2) the effects of TA-specific mAbs with chemo- and/or radio-therapy on CICs; and (3) strategies to overcome this resistance.

Resistance of Cancer Initiating Cells from TA-Specific mAb-based Immunotherapy

1. Characteristics of CICs in Various Types of Tumors

According to the cancer stem cell theory, CICs are a subpopulation of tumor cells that, like normal stem cells, are “multipotent” since they can give rise to all cell types found in a particular cancer sample, are asymmetrically self-renewing, can divide indefinitely, and are able to generate tumor spheres and are tumorigenic in low numbers in immunodeficient mice [2]. Relevant to the data that we are going to present, CICs are chemo- and radio-resistant and are believed to play a major role in both the metastatic spread and disease recurrence, the major causes of patients morbidity and mortality [3]. Therefore, CICs cells have to be eradicated in order to “cure” a malignant disease.

Several markers have been reported to identify CICs in various types of tumors. They include CD44^{high}CD24^{low} in breast cancer [4], CD133 in pancreas ductal adenocarcinoma (PDAC) [5] and in osteosarcoma [6], and the activity of the aldehyde dehydrogenases (ALDHs) in head and neck, breast, lung, pancreas, colon, prostate, and ovary cancers and osteosarcoma [2, 7–13].

According to the information in the literature and our own data, the ALDH activity appears to be a reliable marker. Since this marker has been used in studies we are going to present, we will first give some background about the ALDH activity in normal and cancer cells. ALDHs are a family of enzymes involved in the maintenance of cellular homeostasis by metabolizing both endogenous and

exogenous reactive compounds [14]. They oxidize aldehydes to the corresponding carboxylic acids using either Nicotinamide adenine dinucleotide (NAD) or nicotinamide adenine dinucleotide phosphate (NADP) as a coenzyme [15]. These enzymes are known to modulate several cell functions, including proliferation, differentiation and survival as well as the cellular response to oxidative stress. How ALDHs modulate these processes still remain to be determined. Nineteen ALDH genes have been found in the human genome [16]. They are clustered in 11 families and 4 subfamilies with distinct chromosomal locations. ALDHs, namely, ALDH1A2, ALDH1A3, ALDH1A7, ALDH2*2, ALDH3A1, ALDH4A1, ALDH5A1, ALDH6 and ALDH9A1 display high enzymatic activity in normal and cancer stem cells. Therefore, these enzymes may be considered a marker for these cells and may well play a functional role in terms of self protection, differentiation, and/or expansion of stem cell populations.

The detection of ALDH in a cell relies on the measurement of its enzymatic activity. This has been facilitated by the availability of a specific substrate which can be detected by fluorescence analysis (ALDEFLUOR). It is noteworthy that this substrate does not discriminate among different isoforms of ALDHs. Therefore, as ALDH isoforms have a wide substrate spectrum, it has been possible to determine that ALDH positivity, evidenced in various types of stem cells, including cancer stem cells, is not due to the expression of the same isoforms. It is believed that this heterogeneity indicates that the isoform responsible for Adelfluor activity in the case of normal cells depends on the type of the cell and on the tissue of origin in the case of cancer cells [17]. That is why most studies on ALDHs and stem cells do not specify the ALDH isoform, but speak rather generically of ALDH. However, ALDH1 has been identified as a marker for the isolation and identification of normal or cancer stem cells [2], and along with ALDH3A1, which it has been shown to play a role in differentiation and cell proliferation [15]. Indeed, a reduction in cell proliferation has been observed when the enzyme is directly inhibited by the administration of synthetic specific inhibitors, antisense oligonucleotides, or siRNA.

Several lines of evidence indicate that cells which display high activity of ALDH (ALDH^{bright}) are normal or cancer stem cells. The enzymatic activity of ALDHs in human hematopoietic progenitor cells has been shown to be higher than in more mature hematopoietic cells [18]. In addition, it has been associated with an enhanced repopulating function and cellular resistance to cytotoxic drugs such as alkylating agents. As multipotent cells, ALDH^{bright} cells isolated from bone marrow have been demonstrated to include hematopoietic, endothelial, mesenchymal, and neural progenitor cells, which are crucial in repair protocols for various pathological conditions. Like human hematopoietic progenitor cells, several other types of normal stem cells have been shown to display high levels of cytosolic ALDH expression. They include neural cells, myogenic cells, mammary cells, prostate cells, and intestinal crypt cells. These cells have been shown to be multipotent, self-renewing, and able to generate spheres and epithelial stem-like cells in culture.

Increased ALDH activity in cancer stem cells was first reported in acute myeloid leukemia. Subsequently, similar observations have been reported for several types of solid cancers, including breast, colon, prostate, lung, pancreas and

ovary. Our data as well as data from the literature demonstrate that ALDH^{bright} cells in head and neck, triple negative breast and pancreatic cancers have the characteristic of CICs, such as *in vitro* self-renewal, chemo- and radio-resistance, ability to divide indefinitely, aberrant regulation of several stem cell signaling pathways (such as Hedgehog and MAPK, Notch, PI3K/AKT, TGF- β and Wnt), expression of stem cell markers, tumor cell sphere formation, and high tumorigenicity at low cell numbers in SCID mice [19–21].

ALDH^{bright} cells are analyzed using the ALDEFLUORTM reagent kit. The activated ALDEFLUORTM Reagent, BODIPYTM-aminoacetaldehyde (BAAA), is a fluorescent non-toxic substrate for ALDH, which freely diffuses into intact and viable cells. In the presence of ALDH, BAAA is converted into BODIPYTM-aminoacate (BAA), which is retained inside the cells. The amount of fluorescent reaction product is proportional to the ALDH activity in the cells and is measured using a flow cytometer. The active efflux of the reaction product is inhibited by an efflux inhibitor in the ALDEFLUORTM Assay Buffer. A specific inhibitor of ALDH, diethylaminobenzaldehyde (DEAB), is used to control for background fluorescence as the gating reference standard of the ALDH^{neg} population. Thus, ALDH^{bright} cells are those ALDH⁺ cells with twice the mean fluorescence intensity (MFI) of the ALDH⁺ cell population (Fig. 1). The frequency of ALDH^{bright} cells varies among cell lines of different tumor types as well as among cell lines from the same type of tumor. Table 2 presents the results we have obtained with different human cancer cell lines analyzed for the content of ALDH^{bright} cells. It is noteworthy that this frequency is influenced by the culture conditions such as cell confluency, cell starvation and hypoxia [22]. Viable ALDH^{bright} cells can be




Fig. 1 ALDH activity expression as a marker of CICs in the human ovarian cancer cell line SK-OV-3 and in the human PDAC cell line MIA PaCa-2. SK-OV-3 and MIA PaCa-2 cells (2.5×10^5) were cultured in complete medium at 37 °C, 5 % CO₂. Then, the cells were harvested and stained with ALDEFLUOR with or without the DEAB inhibitor to identify ALDH^{bright} cells. ALDH^{bright} cells were identified as those ALDH⁺ cells with twice the mean fluorescence intensity (MFI) of the ALDH⁺ cell population

Table 2 Expression of ALDH⁺ and ALDH^{bright} cells in different types of cancer

Cell line	ALDH ⁺ cells (%)	ALDH ^{bright} cells (%)
<i>Head and neck cancer</i>		
PCI-4A	23.2	6.3
PCI-13	11.3	1.9
PCI-30	0.3	0.1
PCI-37A	1.2	0.1
SCC-4	5.4	1.1
SCC-90	1.6	0.2
SCC-104	0.5	0.1
UD-SCC-4	0.5	0.1
UD-SCC-6	0.3	0.1
FaDu	1.8	0.1
<i>Breast cancer</i>		
MDA-MB-231	18.2	0.7
SUM-149	22.1	1.5
UACC-812	4.7	0.3
<i>Pancreatic cancer</i>		
MIA PaCa-2	43.2	4.6
S2-LM7-AA	19.3	1.6
PDAC1	21.3	2.5
PDAC2	14.4	2.3
PDAC3	38.2	8.0
PDAC5	5.7	0.8

further isolated using a cell sorter and can be tested for their ability to form tumor spheres *in vitro* and for their tumorigenicity in low number in immunodeficient mice. As shown in Fig. 2, ALDH^{bright} cells sorted from the head and neck cancer PCI-13 cell line, the PDAC MIA PaCa-2 cell line, and the TNBC MDA-MB-231-Luc cell line orthotopically injected at a low number (500 cells/mouse) in immunodeficient mice induce tumors in most if not in all of the injected mice. On the other hand, the ALDH^{neg} cells failed to induce tumors.

2. Characteristics of the TA Utilized to Target Differentiated Tumor Cells and CICs in Our Laboratory

We have focused our work aiming at developing immunotherapy of solid tumors with TA-specific mAbs on three types of TA which are characterized by a high expression on the tumor cell membrane, a restricted distribution in normal tissue and the ability to modulate multiple signaling pathways. We will describe the characteristics of these TAs which are most relevant for the experiments discussed below.

A. Chondroitin Sulfate Proteoglycan 4

In the late 70s, utilizing mAb elicited in mice immunized with cultured human melanoma cells, we identified a TA with high expression on the membrane of melanoma cells and with a restricted distribution in normal tissues. This TA, which is highly conserved through phylogenetic evolution, consists of an N linked




Fig. 2 Tumorigenicity of ALDH^{bright} cells sorted from human carcinoma cell lines. Immuno-deficient NOD/SCID mice were challenged in the right and left flanks with 500 sorted ALDH^{bright} or ALDH^{neg} PCI-13 or MIA PaCa-2 cells isolated from human carcinoma cell lines and established xenografts and photographs of representative mice are shown. Xenografts were established in 3/3 mice challenged with ALDH^{bright} PCI-13 and 2/3 mice challenged with ALDH^{bright} MIA PaCa-2 cells (*left panel*). Sorted ALDH^{bright} and ALDH^{neg} MDA-MB-231-luc-D3H1 (Xenogen Corp) cells (500/mouse) were mixed with irradiated unsorted MDA-MB-231 cells (10,000/mouse) and Matrigel and injected (total final vol. 100 μ l) intraperitoneally (i.p.) into 2 groups of NOD/SCID mice. Tumor growth was monitored in each mouse weekly by Bioluminescence imaging (*right panel*)

280 kDa glycoprotein and a 450 kDa chondroitin sulfate proteoglycan, the two components have the same polypeptide moiety [23]. Because of its large size, we named this TA high molecular weight- melanoma associated antigen. This TA, also known as cell surface chondroitin sulfate proteoglycan 4 (CSPG4), melanoma-associated chondroitin sulfate proteoglycan (MCSP) or neuron-gial antigen 2 (NG2), is expressed not only on melanoma but also on head and neck cancer, TNBC, mesothelioma, chordoma, chondrosarcoma and osteosarcoma [24]. In the tumors which have been analyzed, CSPG4 has been found to be expressed not only on differentiated cancer cells but also on CICs, defined as ALDH^{bright} cells, in head and neck cancer, triple negative breast cancer and osteosarcoma. A representative example of a double staining of ALDH^{bright} cells with a CSPG4-specific mAb in the TNBC MDA-MB-231 cell line is shown in Fig. 3. The expression of CSPG4 on CICs is also corroborated by functional data. Specifically, CSPG4 specific-mAb can inhibit the proliferation and the migration of TNBC and osteosarcoma cell lines *in vitro* (Figs. 4 and 5) and their ability to metastasize when injected in immunodeficient mice [25]. Furthermore, CSPG4-specific mAb could suppress disease recurrence and prolong survival in mice which have been grafted with the TNBC cell line MDA-MB-231 and then subjected to surgical removal of the primary tumor (Fig. 6). As already discussed, CICs play a major role in disease




Fig. 3 CSPG4 expression on human TNBC CICs. The TNBC cells MDA-MB-231 were incubated with ALDEFLUOR (Stem Cell Technologies) to detect ALDH activity and stained with the CSPG4-specific mAb 225.28. DEAB, a specific inhibitor of ALDH, was used to establish the baseline fluorescence of these cells. The isotype matched mAb F3-C25 was used as a control for the CSPG4-specific mAb 225.28. The ALDH^{bright} cells were identified as those ALDH⁺ cells with twice the mean fluorescence intensity (MFI) of the ALDH⁺ cell population. The % of cells stained by ALDEFLUOR and/or by mAbs is shown




Fig. 4 Inhibition of human osteosarcoma U2OS carcinoma cell growth. Human osteosarcoma U2OS cells were serum starved 3 days and incubated either with 0.25 mg/ml CSPG4-specific mAb 225.28 or control mAb F3-C25 in a 3-D (matrigel) setting for 10 days. PBS, which was used as the solvent for both mAbs, was used as a reference for 100 % cell growth. Cells in each well were harvested from the matrigel using the Cell Recovery Solution (BD Pharmingen) and counted by two individuals using Trypan Blue. The results are expressed as % inhibition of cell growth, utilizing the values obtained for cells grown in PBS, as a reference. The values shown are the mean of three independent experiments. *** indicates $p < 0.001$

recurrence and metastatic spread. The effects of immunotherapy with the CSPG4-specific mAb are mediated by the inhibition of the activation of multiple signaling components of pathways involved in proliferation, survival and antiapoptotic signals as well as in migration of cancer cells including CICs (Fig. 7). The potential clinical relevance of these data is indicated by the beneficial effect of the clinical course of the disease of CSPG4-specific antibodies induced by CSPG4 mimics in patients with melanoma.




Fig. 5 Inhibition of human osteosarcoma U2OS carcinoma cell migration. U2OS cells were serum starved 3 days and seeded and incubated with either 0.5 mg/ml CSPG4-specific mAb 225.28, control mAb F3-C25 or PBS in a migration assay. Pictures of each well were taken with a Zeiss Inverted Fluorescence Microscope (AxioVision Software) ($\times 200$). The results are expressed as % inhibition of migration, utilizing the values obtained in PBS without mAb as a reference. The values shown are the mean of three independent experiments. *** indicates $p < 0.001$




Fig. 6 Prolongation of mice survival by the CSPG4-specific mAb after surgical removal of the primary tumor derived by TNBC MDA-MB-231 cells. TNBC MDA-MB-231 cells (2×10^6 cells/mouse) were injected orthotopically into 20 SCID mice. After 63 days, mice were divided into two groups ($n = 10/\text{group}$) using a stratified randomization strategy, such that the mean tumor volume was not statistically significantly different between two groups. On day 63, all primary tumors were surgically removed. Starting from day 66, mice were treated intravenously (i.v.) with CSPG4-specific mAb 225.28 (200 $\mu\text{g}/\text{mouse}/\text{twice per week}$) or control mAb F3-C25 (200 $\mu\text{g}/\text{mouse}/\text{twice per week}$). The survival of mice was analyzed using the Kaplan–Meier survival curve




Fig. 7 Effect of the CSPG4-specific mAb 225.28 on multiple signaling pathways *in vitro* in the human osteosarcoma MG-63 cell line. The human osteosarcoma cell line MG-63 was incubated with either the CSPG4-specific mAb 225.28, the isotype control mAb F3-C25 or PBS for 72 h at 37 °C. Cell lysates were tested in western blot with anti-phosphorylated (p)-MET, MET, β-catenin, p-FAK, PKCα, p-PDK1, p-AKT antibodies. HLA class I heavy chain (HLA class I) was used as the loading control

B. Glucose-regulated Protein of 94 kDa

The heat shock protein (HSP) glucose-regulated protein of 94 kDa (Grp94) is a member of the HSP90 family [26, 27]. Similar to other members of this family, the molecular chaperone Grp94 is required for the stability and activity of client proteins involved in the activation of signaling pathways associated with tumor cell survival and proliferation [27–29]. These functional properties of Grp94 provide a molecular mechanism for the anti-proliferative effect and the induction of apoptosis of malignant cells by Grp94 inhibitors. The potential clinical relevance of these findings is suggested by the clinical responses observed in patients treated with inhibitors of HSP90 [30–32], which display a high degree of homology with Grp94. However, the clinical use of HSP90 inhibitors is hampered by the significant side effects they cause because of their lack of selectivity and the ubiquitous intracellular expression of HSP90. To overcome these limitations, we have isolated a Grp94-specific single chain Fv fragment from a phage display antibody library. This single chain has the unique specificity to recognize an extracellular epitope of Grp94 which is selectively expressed on the membrane of many types of malignant cells, but has a restricted distribution in normal cells. In the tumors we have analyzed, Grp94 has been found to be expressed not only on differentiated cancer cells but also on CICs, defined as ALDH^{bright} cells. A representative example of a double staining of ALDH^{bright} cells with a Grp94-specific mAb in the PDAC MIA-PaCa-2 cell line is shown in Fig. 8. The Grp94-specific mAb inhibits the proliferation and the migration of malignant cells and induces their apoptosis. These effects are mediated by inhibition of the activation of several components of signaling pathways involved in proliferation, survival and anti-apoptosis as well as in migration of cancer cells including CICs (data not shown).




Fig. 8 Grp94 expression on human TNBC CICs. The TNBC cells MDA-MB-231 were incubated with ALDEFLUOR (Stem Cell Technologies) to detect ALDH activity and stained with the Grp94-specific mAb W9. DEAB, a specific inhibitor of ALDH, was used to establish the baseline fluorescence of these cells. The isotype matched mAb HlgG1 was used as a control for the mAb W9. ALDH^{bright} cells were identified as those ALDH⁺ cells with twice the mean fluorescence intensity (MFI) of the ALDH⁺ cell population. The % of cells stained by ALDEFLUOR and/or by mAbs is shown

C. B7-H3

B7-H3 known also as CD276 is a member of the B7 family; it shares 20–27 % amino acid sequence homology with other members of the B7 family [33]. To detect B7-H3, we use the mAb 376.96, an IgG2a generated from a BALB/c mouse hyperimmunized with cultured human melanoma cells. The specificity of mAb 376.96 for B7-H3 has been recently shown by the following lines of evidence. First, mass spectrometry analysis of the peptides generated by trypsin digestion of the 94 kDa glycoprotein immunoprecipitated by mAb 376.96 from cultured human melanoma Colo38 cells has demonstrated a high degree of homology with that of B7-H3. Second, the mAb 376.96 specifically reacts with purified B7-H3 in binding assays. Third, the mAb 376.96 stains CHO cells transfected with human B7-H3 (2Ig) or B7-H3 (4Ig) cDNA; the epitope recognized by the mAb 376.96 is expressed on both 2 and 4Ig human B7-H3. Immunohistochemical staining with the B7-H3-specific mAb 376.96 has shown that the corresponding epitope has a broad distribution on several types of cancer including head and neck, breast, pancreatic, ovarian, prostate cancer and osteosarcoma. In contrast, this epitope has a more restricted distribution than the B7-H3 molecules in normal tissues since several tissues which express the B7-H3 molecule are not stained by the B7-H3-specific mAb 376.96. In the tumors we have analyzed, the B7-H3-specific mAb 376.96 has been found to be expressed not only on differentiated cancer cells but also on CICs, defined as ALDH^{bright} cells. A representative example of a double




Fig. 9 B7-H3-specific mAb 376.96 expression on human PDAC MIA PaCa-2 CICs. MIA PaCa-2 cells were incubated with ALDEFLUOR (Stem Cell Technologies) to detect ALDH activity and stained with the B7-H3-specific mAb 376.96. DEAB, a specific inhibitor of ALDH, was used to establish the baseline fluorescence of these cells. The isotype matched mAb F3-C25 was used as a control for the mAb 376.96. ALDH^{bright} cells were identified as those ALDH⁺ cells with twice the mean fluorescence intensity (MFI) of the ALDH⁺ cell population. The % of cells stained by ALDEFLUOR and/or by mAbs is shown

staining of ALDH^{bright} cells with the B7-H3-specific mAb 376.96 in the PDAC Mia-PaCa-2 cell line is shown in Fig. 9. The mAb 376.96 displays an antiproliferative effect *in vitro* with various types of cell lines including TNBC, PDAC and ovarian cancers. These results are paralleled by the inhibition of PDAC cell growth grafted in immunodeficient mice (Fig. 10). Studies in progress suggest that this effect is mediated by the inhibition of the activation of several components of signaling pathways involved in proliferation, survival and antiapoptosis as well as in migration of cancer cells including CICs (Fig. 11).

Effects of TA-specific MAbs in Combination with Chemo-radio-therapy on CICs

The results shown above in the previous sections indicate that TA-specific mAbs have anti-tumor effects by inhibiting cell growth, cell migration, and inducing apoptosis *in vitro*. These effects are paralleled by an inhibition but not complete suppression of metastatic spread and disease recurrence in immunodeficient mice grafted with human cancer cell lines. These findings are likely to reflect the inability of TA-specific mAbs to eliminate CICs. This possibility is supported by our *in vitro* data which have shown that incubation of cell lines with the




Fig. 10 Inhibition by the B7-H3-specific mAb 376.96 on the growth of tumors derived from the human PDAC MIA PaCa-2 cells grafted in SCID mice. Ten SCID mice were orthotopically challenged by the human PDAC cell line MIA PaCa-2 (2×10^6 /mouse). After 28 days, the mice were randomly divided into 2 groups ($n = 5$ /group). One group was treated i.v. with the B7-H3-specific mAb 376.96 (200 μ g/mouse) and the other group was treated i.v. with the control mAb F3-C25 (200 μ g/mouse) twice per week. After a total of 8 treatments, one mouse from the control group was dead and all other mice in the control group have ascites. In contrast, no mouse in the mAb 376.96-treated group had ascites. The pictures of mice on day 56 are shown in the left panel and the average diameters of the abdomen from both groups are shown in the right panel. **: p value < 0.01




Fig. 11 Effect of the B7-H3-specific mAb 376.96 on multiple signaling pathways *in vitro* in the human osteosarcoma MG-63 cell line. The human PDAC cells MIA PaCa-2, PANC 1 and the human osteosarcoma cell line MG-63 were incubated for 48 h (MIA PaCa-2 and PANC 1) or 72 h (MG-63) at 37 $^{\circ}$ C with either the B7-H3-specific mAb 376.96 or the control mAb F3-C25. Cells incubated in medium without mAbs were used as control. Cell lysates were tested by western blot with phosphorylated (p)-FAK, FAK, PKC α , p-ERK1/2, ERK1/2, p-AKT, AKT, β -catenin, PI3K 110 α and p-PDK1 mAbs. HLA class I was used as a loading control




Fig. 12 Inhibition of pancreatic CICs *in vitro* proliferation by the Grp94-specific mAb W9. The PDAC MIA PaCa-2 cells were incubated with the mAb W9 (20 µg/ml), cyclopamine (20 µM), and 5-FU (10 µM) for 48 h at 37 °C. Cells were then harvested and stained with ALDEFLUOR with or without DEAB. HlgG1 was used as an isotype control. The triple combination of mAb W9, cyclopamine and 5-FU was significantly ($p < 0.05$) more effective than the triple combination of HlgG1, cyclopamine and 5-FU, double combinations and individual agents. The double combination of mAb W9 and cyclopamine was significantly ($p < 0.05$) more effective than the other combinations of two agents and individual agents. Cyclopamine was significantly ($p < 0.05$) more effective than the other individual agents

CSPG4/Grp94/B7-H3-specific mAbs can reduce the percentage of ALDH^{bright} cells but not completely eliminate them. Representative examples of the effect of TA-specific mAbs on CICs are shown in Figs. 12 and 13. The detrimental effect of TA-specific mAbs on the percentage of CICs can be enhanced by combining the mAbs with chemotherapeutic agents, novel targeted agents and/or radiotherapy. Representative examples are shown in Figs. 12 and 13. The antiproliferative activity of the Grp94-specific mAb on differentiated PDAC cells as well as on pancreatic CICs is significantly enhanced when PDAC cells are incubated with the Grp94-specific mAb in combination with 5FU or with radiation (Fig. 14).

Enhancement by Signaling of the CICs Pathway Inhibitor of the Detrimental Effects of TA-specific MAb on CICs

The antitumor effects of TA-specific mAbs on both differentiated cancer cells and CICs have been shown to be enhanced by combining TA-specific mAbs with chemotherapeutic agents, targeted agents or radiotherapy. However, these types of combinatorial strategies do not completely eliminate CICs from a tumor cell population. These *in vitro* results provide an explanation for the limited duration of clinical objective responses of tumor-bearing hosts treated with TA-specific mAbs in combination with chemotherapeutic agents, targeted agents or radiotherapy. The fraction of CICs which is not eradicated by this combinatorial therapy may cause disease recurrence. These findings emphasize the need to develop novel and




Fig. 13 Inhibition of pancreatic CICs *in vitro* proliferation by the Grp94-specific mAb W9. The PDAC MIA PaCa-2 cells were incubated with the mAb W9 (20 µg/ml), cyclopamine (20 µM), and radiotherapy (20 Gy). Following a 72 h incubation at 37 °C, the cells were harvested and stained with ALDEFLUOR with or without DEAB. HlgG1 was used as isotype control. The triple combination of mAb W9, cyclopamine and 20 Gy was significantly ($p < 0.05$) more effective than the triple combination of HlgG1, cyclopamine and 20 Gy, double combinations and individual treatment. The double combination of mAb W9 and cyclopamine was significantly ($p < 0.05$) more effective than the other combinations of two agents and individual agents. Cyclopamine was significantly ($p < 0.05$) more effective than the other individual treatments




Fig. 14 Inhibition of cell growth in PDAC cells by the mAb W9, cyclopamine and 5-FU Cells (4×10^5 /ml) were starved for 3 h, then incubated with the mAb W9 (20 µg/ml), cyclopamine (20 µM), and 5-FU (10 µM) in RPMI 1,640 medium containing 1.5 % FCS. Cells were then tested by the MTT assay. HlgG1 was used as a negative control. Results were shown as OD value and error bars were presented as standard deviation. The mAb W9, cyclopamine, and 5-FU combination was significantly ($p < 0.01$) more effective than the HlgG1, cyclopamine, and 5-FU combination, dual-agent combinations, and individual agents

effective therapeutic strategies which completely eradicate differentiated cancer cells and CICs. In addressing this need, we have been guided by the realization that signaling pathways involved in proliferation and survival are aberrantly activated in CICs. Inhibition of these signaling pathways has been shown to suppress CICs growth *in vitro* and in immunodeficient mice. However, also in this case, the eradication of CICs is not complete. Therefore, we have tested whether the detrimental effect on CICs by TA-specific mAbs could be enhanced by combination with chemotherapy or radiotherapy and by inhibitors of the CIC signaling pathways. Several pathways have been shown to be activated in CICs. They include the Sonic Hedgehog Homologue (SHH), MAPK, Notch, PI3 K/AKT, TGF- β and Wnt pathways [34, 35]. Since in the types of tumors that we investigated the SHH pathway has been found to be aberrantly activated in CICs, we have tested whether combining TA-specific mAbs and/or chemoradio-therapy with cyclopamine, an inhibitor of the SHH pathway, could eradicate CICs. Our *in vitro* results demonstrate that this is indeed the case at least in the tumor we have investigated. A representative example is shown in Figs. 12 and 13. Treatment of the PANC2.03, PANC3.27 and Mia-PaCa2 PDAC cell lines with the Grp94-specific mAb in combination with 5FU or radiotherapy and cyclopamine eliminate more than 90 % of the CICs in a tumor cell population. This effect is mediated by the inhibition of activation of multiple components of signaling pathways involved in proliferation, survival, antiapoptotic signals and CICs proliferation (Fig. 15).




Fig. 15 Inhibition of signaling pathways in MIA PaCa-2 PDAC cells by the mAb W9, cyclopamine and 5-FU. The MIA PaCa-2 cells were incubated with the Grp94-specific mAb W9 (20 μ g/ml), cyclopamine (20 μ M) and 5-FU (10 μ M) for 48 h at 37 $^{\circ}$ C. Cell lysates were then prepared and tested by western blot with the corresponding antibodies (Cell Signaling Technology). Calnexin was used as the loading control. Cells incubated with the mAb W9 alone, with the mAb W9 and cyclopamine, with cyclopamine alone, with the mAb W9 and 5-FU and with 5-FU alone were used as controls

Conclusions

Convincing experimental and clinical evidence indicate that TA-specific mAbs represent valuable reagents for the treatment of various types of cancer. However, a major limitation of this type of immunotherapy is its limited efficacy in time because of the occurrence of metastatic spread and/or disease recurrence, the two major causes of patients morbidity and mortality. According to the cancer stem cell theory, both complications may be mediated by CICs, a cellular subpopulation that displays stem cell properties and drives and maintains the growth of many types of cancer. In the experiments described in this chapter, we have tested this possibility by assessing the sensitivity of CICs to the detrimental effects of TA-specific mAbs. The *in vitro* data we have obtained utilizing three TA systems in several types of solid tumors indicate that CICs have a limited sensitivity to the detrimental effects of TA-specific mAbs even when they are combined with chemotherapeutic agents, targeted agents or radiotherapy. These combinations can eliminate only part of the CICs present in a tumor cell population. Whether the differential sensitivity of CICs to TA-specific mAbs in combination with chemotherapy, targeted therapy or radiotherapy reflects differences in their differentiation stage and/or epigenetic changes remains to be determined. Whatever the mechanism, if these *in vitro* findings reflect what happens in tumor-bearing hosts treated with TA based immunotherapy, then our data provide a mechanism for the disease recurrence which frequently occurs in patients treated with TA-specific mAb-based immunotherapy. Our *in vitro* data also suggest that the ability of TA-specific mAbs in combination with chemotherapeutic agents, targeted agents or radiotherapy to eradicate CICs can be markedly enhanced by inhibitors of signal transduction pathways that are aberrantly activated in CICs. These results have to be interpreted with caution since they were obtained with established cell lines and *in vitro* experiments. Nevertheless, the potential impact of this combinatorial strategy on disease recurrence in patients treated with TA-specific mAbs-based immunotherapy urges the implementation of *in vivo* experiments to assess the potential clinical relevance of the *in vitro* data we have described. Can the treatment of tumor-bearing hosts with TA-specific mAbs-based immunotherapy in combination with chemotherapeutic agents, targeted agents or radiotherapy and inhibitors of CIC signaling pathways cure a malignant disease? Can the monitoring of the percentage of CICs present in a tumor-bearing host be used to optimize the combinatorial therapy administered to a tumor bearing patient? Our results may also provide a mechanism for the failure observed in clinical trials which have tested the clinical efficacy of CIC signaling pathway inhibitors. An example is represented by the lack of clinical efficacy which has been reported for cyclopamine in patients with PDAC. Our *in vitro* results suggest that this failure can reflect the limited efficacy of cyclopamine [36] in eliminating differentiated cancer cells and CICs when it is used as a single agent. However, our data argue that this compound enhances the ability of TA-specific mAbs in combination with chemotherapeutic agents, targeted agents or radiotherapy in eliminating CICs.

This finding is not unique of cyclopamine since a recent clinical trial has demonstrated that agents which inhibit CIC signaling pathways such as cabozantinib, a c-Met inhibitor, and Trastuzumab, a HER2-specific mAb, have clinical efficacy in advanced castration-resistant prostatic cancer when they are used in combination, although the two agents failed when used as single agents [37–39].

In summary, our *in vitro* data strongly suggest that lack of complete elimination of CICs by TA-specific mAbs in combination with chemotherapeutic agents, targeted agents or radiotherapy plays a major role in disease recurrence which represents a significant obstacle to the successful clinical efficacy of TA-specific mAbs. The *in vivo* relevance of these *in vitro* data has to be tested in animal model systems since the resulting information may represent a useful background for a rational design of an effective clinical strategy.

Acknowledgments This work was supported by PHS grants RO1CA138188 and RO1CA110249 awarded by the National Cancer Institute and Susan Komen Post Doctoral Fellowship KG111486 awarded by the Susan G. Komen for the Cure Foundation.

Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immuno escape. *J Clin Oncol: Official J Am Soc Clin Oncol*. 2010;28:4390–9.
2. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*. 2007;1:555–67.
3. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea—a paradigm shift. *Cancer research*. 2006;66:1883–90, discussion 95–6.
4. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. *Breast Cancer Res: BCR*. 2008;10:105.
5. Matsuda Y, Kure S, Ishiwata T. Nestin and other putative cancer stem cell markers in pancreatic cancer. *Med Mol Morphol*. 2012;45:59–65.
6. Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, et al. CD133 expression in osteosarcoma and derivation of CD133(+) cells. *Mol Med Rep*. 2013;7:577–84.
7. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. *Cancer Res*. 2007;67:10538–45.
8. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, Lin SB. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. *Cancer Lett*. 2013;328:144–51.
9. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. *PLoS One*. 2011;6:e20636.

10. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Büttow R, Coukos G, Zhang L. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. *PLoS ONE*. 2010;5:e10277.
11. Sanders MA, Majumdar AP. Colon cancer stem cells: implications in carcinogenesis. *Front Biosci: J Virtual Library*. 2011;16:1651–62.
12. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. *Lab Invest; J Tech Methods pathol*. 2010;90:234–44.
13. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. *Oncol Rep*. 2010;24:501–5.
14. Vasilou V, Pappa A, Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. *Drug Metab Rev*. 2004;36:279–99.
15. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. *Free Radical Biol Med*. 2012;52:735–46.
16. Jackson B, Bocker C, Thompson DC, Black W, Vasilou K, Nebert DW, Vasilou V. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. *Human Genom*. 2011;5:283–303.
17. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. *Cell Cycle*. 2011;10:1378–84.
18. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. *Proc Natl Acad Sci USA*. 1999;96:9118–23.
19. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer Res*. 2006;66:9339–44.
20. Lauth M. RAS and Hedgehog—partners in crime. *Front Biosci*. 2011;17:2259–70.
21. Visvader JE. Cells of origin in cancer. *Nature*. 2011;469:314–22.
22. Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. *Cell Cycle*. 2007;6:2554–62.
23. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. *Crit Rev Immunol*. 2004;24:267–96.
24. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. *Adv Cancer Res*. 2010;109:73–121.
25. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. *J Natl Cancer Inst*. 2010;102:1496–512.
26. McLaughlin M, Vandenbroeck K. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery? *Br J Pharmacol*. 2011;162:328–45.
27. Marzec M, Eletto D, Argon Y. GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. *Biochim Biophys Acta*. 2011;1823:774–87.
28. Argon Y, Simen BB. GRP94, an ER chaperone with protein and peptide binding properties. *Semin Cell Dev Biol*. 1999;10:495–505.
29. Yang Y, Li Z. Roles of heat shock protein gp96 in the ER quality control: redundant or unique function? *Mol Cells*. 2005;20:173–82.
30. de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. *Clin Cancer Res: Official J Am Assoc Cancer Res*. 2008;14:6663–73.

31. Tse AN, Klimstra DS, Gonen M, Shah M, Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, Chung K, Maki R, Lefkowitz R, Brown K, Manova-Todorova K, Wu N, Egorin MJ, Kelsen D, Schwartz GK. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. *Clin Cancer Res: Official J Am Assoc Cancer Res.* 2008;14:6704–11.
32. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. *Clin Cancer Res: Official J Am Assoc Cancer Res.* 2008;14:8302–7.
33. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L. B7–H3: a costimulatory molecule for T cell activation and IFN-gamma production. *Nat Immunol.* 2001;2:269–74.
34. Merchant AA, Matsui W. Targeting Hedgehog—a cancer stem cell pathway. *Clin Cancer Res: Official J Am Assoc Cancer Res.* 2010;16:3130–40.
35. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. *Stem Cell Rev.* 2007;3:7–17.
36. Keeler RF, Baker DC. Oral, osmotic minipump, and intramuscular administration to sheep of the Veratrum alkaloid cyclopamine. *Proceedings of the society for experimental biology and medicine society for experimental biology and medicine.* 1989;192:153–156.
37. Ziada A, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. *Prostate.* 2004;60:332–7.
38. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. *Clin Cancer Res: Official J Am Assoc Cancer Res.* 2013;19:215–24.
39. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothesis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. *J Clin Oncol: Official J Am Soc Clin Oncol.* 2013;31:412–9.
40. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol: Official J Am Soc Clin Oncol.* 2010;28:1254–61.
41. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3 K pathway as a major determinant of trastuzumab resistance in breast cancer. *Cancer Cell.* 2007;12:395–402.
42. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell.* 2004;6:117–27.
43. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). *J Natl Cancer Inst.* 2001;93:1852–7.
44. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O. Insulin-like growth factor-I receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-I receptor and epidermal growth factor receptor in hepatocellular carcinoma. *Clin Cancer Res: Official J Am Assoc Cancer Res.* 2009;15:5445–56.
45. Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. *Critical Rev Oncol/hematology.* 2010;74:73–8.
46. Lin A, Yan WH, Xu HH, Gan MF, Cai JF, Zhu M, Zhou MY. HLA-G expression in human ovarian carcinoma counteracts NK cell function. *Ann Oncol.* 2007;18:1804–9.

47. Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, González M, Mordoh J, Bianchini M. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. *Innate Immun.* 2009;15:91–100.
48. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. *Mol Immunol.* 2003;40:109–23.
49. Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. *Immunopharmacology.* 1999;42:209–18.
50. You T, Hu W, Ge X, Shen J, Qin X. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytotoxicity on cancer cells. *Cell Mol Immunol.* 2011;8:157–63.
51. Dziatczenia J, Wrobel T, Mazur G, Poreba R, Jazwiec B, Kuliczowski K. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma. *Med Oncol.* 2010;27:743–6.
52. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. *Adv Cancer Res.* 2005;93:189–234.
53. Taylor C, Hershman D, Shah N, Suci-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. *Clin Cancer Res: Official J Am Assoc Cancer Res.* 2007;13:5133–43.
54. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. *Cancer Immunol, Immunotherapy: CII.* 2004;53:904–10.
55. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol.* 2006;6:295–307.
56. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer. *Nat Med.* 2007;13:828–35.
57. Xue SA, Stauss HJ. Enhancing immune responses for cancer therapy. *Cell Mol Immunol.* 2007;4:173–84.
58. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. *J Clin Oncol: Official J Am Soc Clin Oncol.* 2008;26:1789–96.
59. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. *J Clin Oncol: Official J Am Soc Clin Oncol.* 2007;25:3712–8.
60. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. *Blood.* 2006;108:1975–8.
61. Pejavar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. *Crit Rev Oncology/hematology.* 2008;67:93–102.
62. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. *Cancer Immunol, immunotherapy: CII.* 2009;58:1853–64.
63. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E. Antibody-dependent cellular

- cytotoxicity mediated by cetuximab against lung cancer cell lines. *Clin Cancer Res: Official J Ame Assoc Cancer Res.* 2007;13:1552–61.
64. Burtneß B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Eastern cooperative oncology G. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. *J Clin Oncol: Official J Am Soc Clin Oncol.* 2005;23:8646–54.
 65. Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. *Exp Hematol.* 2007;35:1801–11.
 66. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. *Cancer Sci.* 2011;102:1–8.
 67. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. *Semin Immunol.* 2008;20:286–95.

Resistance to Immunotherapeutic Antibodies in Cancer
Strategies to Overcome Resistance

Bonavida, B. (Ed.)

2013, XIII, 202 p., Hardcover

ISBN: 978-1-4614-7653-5